Back to top
more

Adverum Biotechnologies (ADVM)

(Real Time Quote from BATS)

$7.75 USD

7.75
113,575

+0.10 (1.31%)

Updated Oct 14, 2024 02:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Adverum Biotechnologies (ADVM) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sanghamitra Saha headshot

What Bargains? Play 5 Stocks With Rising P/E Instead

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 13.33% and 205.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Adverum Biotechnologies (ADVM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Adverum Biotechnologies (ADVM) is a Top Pick for Momentum Investors

by Zacks Equity Research

Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank

    by Zacks Equity Research

    Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank

      Sanghamitra Saha headshot

      Move Beyond Bargain Hunting: 5 Stocks With Rising P/E

      by Sanghamitra Saha

      Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

        Can The Uptrend Continue for Adverum Biotechnologies (ADVM)?

        by Zacks Equity Research

        Investors certainly have to be happy with Adverum Biotechnologies, Inc. (ADVM) and its short term performance.

          What's in Store for Adverum (ADVM) This Earnings Season?

          by Zacks Equity Research

          On Adverum's (ADVM) second-quarter 2018 conference call, investor focus will be on the company's progress with its pipeline candidates.

            5 Biotech Stocks Set to Beat Estimates This Earnings Season

            by Zacks Equity Research

            Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.

              Is a Beat in Store for Epizyme (EPZM) This Earnings Season?

              by Zacks Equity Research

              Epizyme (EPZM) is expected to provide updates on pipeline candidates when it reports Q1 results on May 8.

                Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?

                by Zacks Equity Research

                On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.

                  What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?

                  by Zacks Equity Research

                  On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.

                    The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum

                      3 Healthcare Stocks Set to Beat Q1 Earnings Estimates

                      by Zacks Equity Research

                      Elevated flu activity, aging population, high expenses, and a low tax rate would influence healthcare stocks' earnings in Q1.

                        What's in the Cards for Inovio (INO) This Earnings Season?

                        by Zacks Equity Research

                        Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.

                          Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up?

                          by Zacks Equity Research

                          Envision Healthcare's (EVHC) Q1 earnings should see an upside from higher revenues at both its segments.

                            What's in the Cards for Merrimack (MACK) in Q1 Earnings?

                            by Zacks Equity Research

                            Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.

                              What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)

                              by Zacks Equity Research

                              Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.

                                What's in the Cards for Aerie (AERI) This Earnings Season?

                                by Zacks Equity Research

                                Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).

                                  What Lies Ahead for Ligand (LGND) This Earnings Season?

                                  by Zacks Equity Research

                                  Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.

                                    Is a Beat in the Cards for Perrigo (PRGO) in Q1 Earnings?

                                    by Zacks Equity Research

                                    Perrigo's (PRGO) product purchases and introductions in the Rx segment might shoot up sales in the near future.

                                      Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?

                                      by Zacks Equity Research

                                      Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.

                                        What's in Store for Intrexon (XON) This Earnings Season?

                                        by Zacks Equity Research

                                        Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.

                                          What's in Store for Catalyst (CPRX) This Earnings Season?

                                          by Zacks Equity Research

                                          Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.